Healthcare -
Biotechnology - NASDAQ - US
$ 0.0393
-12.3 %
$ 155 K
Market Cap
-0.02
P/E
1. INTRINSIC VALUE
Balance Sheet
Cingulate Inc.
| Current Assets | 12.7 M |
| Cash & Short-Term Investments | 12.2 M |
| Receivables | 26.3 K |
| Other Current Assets | 423 K |
| Non-Current Assets | 2.2 M |
| Long-Term Investments | 0 |
| PP&E | 2.2 M |
| Other Non-Current Assets | 0 |
| Current Liabilities | 4.97 M |
| Accounts Payable | 1.27 M |
| Short-Term Debt | 2.66 M |
| Other Current Liabilities | 1.04 M |
| Non-Current Liabilities | 2.44 M |
| Long-Term Debt | 2.44 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Cingulate Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 15.6 M |
| Operating Income | -15.6 M |
| Other Expenses | -99 K |
| Net Income | -15.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cingulate Inc.
| Net Income | -15.5 M |
| Depreciation & Amortization | -198 K |
| Capital Expenditures | -212 K |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 0 |
| Others | -23 M |
| Free Cash Flow | -18.7 M |
Wall Street Analysts Price Targets
Cingulate Inc.
CINGW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CINGW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Cingulate Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
8. Profile
Summary
Cingulate Inc. CINGW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 155 K
Dividend Yield
0.00%
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
Contact
1901 West 47th Place, Kansas City, KS, 66205
https://www.cingulate.com
IPO
Date
None
Employees
13
Officers
Ms. Jennifer L. Callahan CPA
Senior Vice President, Chief Financial Officer & Secretary
Dr. Shane J. Schaffer Pharm.D.
Co-Founder, Chief Executive Officer & Chairman of the Board
Dr. Raul R. Silva M.D.
Co-Founder, Executive Vice President & Chief Science Officer
Dr. Matthew N. Brams M.D.
Co-Founder, Executive Vice President & Chief Medical Officer
Dr. Laurie A. Myers M.B.A., Ph.D.
Executive Vice President & Chief Operating Officer
Thomas Dalton
Vice President of Investor & Public Relations